Clinical trial landscape for pneumonia: Evolving agents against bacterial pathogens
Du Feng1, Huixin Jiang1, Hao Deng1
1Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, PR China.
Clinical trials for pneumonia are accelerating, particularly early-phase research, to combat antimicrobial resistance. However, drug development for elderly patients with pneumonia remains critically underrepresented.
Area of Science:
- Global health
- Infectious diseases
- Clinical pharmacology
Background:
- Pneumonia represents a significant global health burden.
- Antimicrobial resistance (AMR) is increasingly complicating treatment paradigms.
- Understanding clinical trial trends is crucial for addressing AMR in pneumonia.
Purpose of the Study:
- To analyze global trends in pneumonia clinical trials.
- To assess the research pipeline's response to antimicrobial resistance.
- To identify gaps in pneumonia drug development, particularly for vulnerable populations.
Main Methods:
- Utilized the INFORMA Database for interventional trials on bacterial pneumonia (1991-2024).
- Searched MeSH terms: 'Community-acquired pneumonia' and 'Hospital-acquired pneumonia'.
- Analyzed trial status, drugs, mechanisms, demographics, and completion dates using trend and goodness of fit tests.
Main Results:
- Identified 2,448 trials across 113 countries.
- Phase I trials significantly increased from 3.00/year (1991-2000) to 14.82/year (2020-2024).
- Top mechanisms: cell wall synthesis, ribosomal subunit, DNA topoisomerase, beta-lactamase inhibitors, and cell membrane.
- Elderly-specific trials accounted for only 2.8% of the total.
Conclusions:
- Early-phase pneumonia drug development is accelerating due to AMR.
- Traditional antimicrobial mechanisms still dominate, but diversification is emerging.
- Significant gaps exist in developing pneumonia therapies for the elderly population.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia III: Complications and Assessment
01:11Clinical Trials: Overview